Source 1review2018Nature Communications
Toolkit/actively targeted nanocarriers
actively targeted nanocarriers
Also known as: actively targeted NCs, novel actively targeted NCs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
none of the actively targeted NCs have advanced past clinical trials. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs.
Usefulness & Problems
Why this is useful
Actively targeted nanocarriers are nanocarrier delivery systems designed to direct cancer therapeutics toward tumors using active targeting strategies. The review centers on why these systems have translated poorly.; cancer therapeutic delivery; active tumor targeting
Source:
Actively targeted nanocarriers are nanocarrier delivery systems designed to direct cancer therapeutics toward tumors using active targeting strategies. The review centers on why these systems have translated poorly.
Source:
cancer therapeutic delivery
Source:
active tumor targeting
Problem solved
They are meant to improve specificity or effectiveness of tumor-directed therapeutic delivery beyond untargeted or passive approaches.; adding targeting logic to nanocarrier-based cancer therapeutic delivery
Source:
They are meant to improve specificity or effectiveness of tumor-directed therapeutic delivery beyond untargeted or passive approaches.
Source:
adding targeting logic to nanocarrier-based cancer therapeutic delivery
Problem links
adding targeting logic to nanocarrier-based cancer therapeutic delivery
LiteratureThey are meant to improve specificity or effectiveness of tumor-directed therapeutic delivery beyond untargeted or passive approaches.
Source:
They are meant to improve specificity or effectiveness of tumor-directed therapeutic delivery beyond untargeted or passive approaches.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
Translation ControlTechniques
No technique tags yet.
Target processes
translationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationoperating role: delivery
development requires criteria and considerations for improved translation
The abstract states that active targeting has not yet produced nanocarriers that advance past clinical trials, so the approach does not by itself solve translation barriers.; none have advanced past clinical trials according to the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review states that no actively targeted nanocarriers had advanced past clinical trials at the time of publication.
The review states that only 15 passively targeted nanocarriers have been approved for clinical use.
approved nanocarrier count 15 nanocarriers
The review proposes criteria and considerations for development of novel actively targeted nanocarriers.
The review frames a gap between many successful pre-clinical targeted delivery studies and limited clinical translation and success.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug actively-targeted-nanocarriers
none of the actively targeted NCs have advanced past clinical trials. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs.
Source:
clinical translation statussupports
The review states that no actively targeted nanocarriers had advanced past clinical trials at the time of publication.
Source:
design guidancesupports
The review proposes criteria and considerations for development of novel actively targeted nanocarriers.
Source:
translation gapsupports
The review frames a gap between many successful pre-clinical targeted delivery studies and limited clinical translation and success.
Source:
Comparisons
Source-stated alternatives
The abstract explicitly contrasts active targeting with passively targeted nanocarriers.
Source:
The abstract explicitly contrasts active targeting with passively targeted nanocarriers.
Source-backed strengths
intended to support targeted delivery approaches for cancer therapeutics
Source:
intended to support targeted delivery approaches for cancer therapeutics
Compared with lipid nanoparticles
The abstract explicitly contrasts active targeting with passively targeted nanocarriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: intended to support targeted delivery approaches for cancer therapeutics.
Relative tradeoffs: none have advanced past clinical trials according to the abstract.
Source:
The abstract explicitly contrasts active targeting with passively targeted nanocarriers.
Compared with passively targeted nanocarriers
The abstract explicitly contrasts active targeting with passively targeted nanocarriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: intended to support targeted delivery approaches for cancer therapeutics.
Relative tradeoffs: none have advanced past clinical trials according to the abstract.
Source:
The abstract explicitly contrasts active targeting with passively targeted nanocarriers.
Ranked Citations
- 1.